eligibility_summary
Eligibility: Adults ≥18 (GCT ≥15) with CLDN6+ locally advanced/recurrent/metastatic ovarian/fallopian/peritoneal, endometrial cancer, or GCT, progressive disease after/without effective standard therapy, ECOG 0–2, life expectancy ≥3 months, adequate organ function. Exclude: prior CLDN6 therapy, platinum‑refractory/rapid ovarian, active CNS mets/meningitis (unless treated/stable), active autoimmune, recent steroids/immunosuppression, major CV/pulm/GI disease, HCV RNA+, HBsAg+ or HBcAb+.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drug/intervention: XmAb541, a biological monoclonal bispecific antibody and T‑cell engager, given IV or SC. Mechanism of action: XmAb541 is designed to bind CLDN6 (claudin‑6) on tumor cells while concurrently engaging T cells, redirecting and activating them to kill CLDN6‑positive cancer cells. Cells/pathways targeted: CLDN6-expressing tumor cells (notably in ovarian, endometrial, and germ cell/testicular cancers) and T lymphocytes recruited for tumor cell lysis. The key pathway is CLDN6 antigen recognition on tumors with T‑cell activation and cytotoxic effector mechanisms.